DFMO

AcronymDefinition
DFMODifluoromethylornithine
DFMODoppler Filter Mixer-Oscillator
DFMODance Floor Make-Out
DFMODivision Financial Management Office
References in periodicals archive ?
'DFMO is so nontoxic that it also could provide a buffer in patients' drug regimens that would help them add other potent medications with more significant side effects,' says Zahnow.
DFMO (difluoromethylornithine) is a drug used for African trypanosomiasis - an insect-borne parasitic disease of humans and other animals.
CCK-8 kit (Yeasen), antibodies against anti-ODC, SSAT (NOVUS), [beta]-actin (boster), secondary anti-mouse, anti-rabbit (Boster) DCFH-DA (Beyotime), Annexin V-FITC (KeyGEN BioTECH), Enhanced chemiluminescence (Thermo), Dulbecco modified Eagle medium (Gibco), foetal bovine serum (Gibco), Tyrisin (Gibco), PrimeScript[TM] RT reagent kit with gDNA Eraser (Takara), SYBR[R] Premix Ex Taq[TM]II (TaKaRa), Apigenin (Aladdin), DFMO (Sigma), and SPD (Sigma) were obtained.
"With the DFMO for example, it's showing substantial reductions in kids after two years.
DFMO is being investigated in human clinical trials to treat some types of cancer, but it hasn't been tested as a potential therapy for Alzheimer's.
"We are all too aware how high the chance of relapse is so we are wasting no time and we fly out to Helen de Vos Children's Hospital in Grand Rapids, Michigan, next week to enrol Alice on a trial of a drug called DFMO that is showing great promise for preventing relapse.
Pentamidine and a- difluoromethylornithine (DFMO) were tested as standard drugs.
Contrary to this study, found pentamidine combined with DFMO (DL alpha difluromethyl Qionithine) was found to be less effective using mouse model for CNS-trypanosomiasis [30].
This combination consisted of sulindac, which is an older, established antiinflammatory medication, and [alpha]-difluoromethylornithine (DFMO), or eflornithine, a failed cancer-therapeutic drug that was later found to be a highly effective depilatory.
In Detroit, Malia is receiving a new experimental treatment using difluoromethylornithine, or DFMO, which is already approved for use for African sleeping sickness and is being used in cancer trials, since it inhibits a key protein in tumor growth.
Eflornithine or diethylfluoromethylornithine (DFMO) is difficult to administer as it requires one slow infusion every six hours for 14 days (56 infusions in total) and its side-effects include seizures, gastrointestinal disorders, and myelosuppression (19).